Streamlined and focused

24/11/21 -"This looks to be the new motto of Merck’s refurbished R&D pipeline. The strong cut in clinical programmes (50% up to 11/11/2021) has been quietly done. This reminds us of 2014/15, when Merck did ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

24/11/21

Download

You may also be interested by these reports :

17/09/25

Novo Nordisk

The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...

25/08/25

PolyPeptide

Attractive return potential remains – Confidence slightly raised

22/08/25

Novonesis

Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...

21/08/25

Siegfried

Guidance reaffirmed while FX and destocking mask momentum

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue